Cargando…
A high-content cellular senescence screen identifies candidate tumor suppressors, including EPHA3
Activation of a cellular senescence program is a common response to prolonged oncogene activation or tumor suppressor loss, providing a physiological mechanism for tumor suppression in premalignant cells. The link between senescence and tumor suppression supports the hypothesis that a loss-of-functi...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3594263/ https://www.ncbi.nlm.nih.gov/pubmed/23324396 http://dx.doi.org/10.4161/cc.23515 |
_version_ | 1782262315189534720 |
---|---|
author | Lahtela, Jenni Corson, Laura B. Hemmes, Annabrita Brauer, Matthew J. Koopal, Sonja Lee, James Hunsaker, Thomas L. Jackson, Peter K. Verschuren, Emmy W. |
author_facet | Lahtela, Jenni Corson, Laura B. Hemmes, Annabrita Brauer, Matthew J. Koopal, Sonja Lee, James Hunsaker, Thomas L. Jackson, Peter K. Verschuren, Emmy W. |
author_sort | Lahtela, Jenni |
collection | PubMed |
description | Activation of a cellular senescence program is a common response to prolonged oncogene activation or tumor suppressor loss, providing a physiological mechanism for tumor suppression in premalignant cells. The link between senescence and tumor suppression supports the hypothesis that a loss-of-function screen measuring bona fide senescence marker activation should identify candidate tumor suppressors. Using a high-content siRNA screening assay for cell morphology and proliferation measures, we identify 12 senescence-regulating kinases and determine their senescence marker signatures, including elevation of senescence-associated β-galactosidase, DNA damage and p53 or p16(INK4a) expression. Consistent with our hypothesis, SNP array CGH data supports loss of gene copy number of five senescence-suppressing genes across multiple tumor samples. One such candidate is the EPHA3 receptor tyrosine kinase, a gene commonly mutated in human cancer. We demonstrate that selected intracellular EPHA3 tumor-associated point mutations decrease receptor expression level and/or receptor tyrosine kinase (RTK) activity. Our study therefore describes a new strategy to mine for novel candidate tumor suppressors and provides compelling evidence that EPHA3 mutations may promote tumorigenesis only when key senescence-inducing pathways have been inactivated. |
format | Online Article Text |
id | pubmed-3594263 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Landes Bioscience |
record_format | MEDLINE/PubMed |
spelling | pubmed-35942632013-03-22 A high-content cellular senescence screen identifies candidate tumor suppressors, including EPHA3 Lahtela, Jenni Corson, Laura B. Hemmes, Annabrita Brauer, Matthew J. Koopal, Sonja Lee, James Hunsaker, Thomas L. Jackson, Peter K. Verschuren, Emmy W. Cell Cycle Report Activation of a cellular senescence program is a common response to prolonged oncogene activation or tumor suppressor loss, providing a physiological mechanism for tumor suppression in premalignant cells. The link between senescence and tumor suppression supports the hypothesis that a loss-of-function screen measuring bona fide senescence marker activation should identify candidate tumor suppressors. Using a high-content siRNA screening assay for cell morphology and proliferation measures, we identify 12 senescence-regulating kinases and determine their senescence marker signatures, including elevation of senescence-associated β-galactosidase, DNA damage and p53 or p16(INK4a) expression. Consistent with our hypothesis, SNP array CGH data supports loss of gene copy number of five senescence-suppressing genes across multiple tumor samples. One such candidate is the EPHA3 receptor tyrosine kinase, a gene commonly mutated in human cancer. We demonstrate that selected intracellular EPHA3 tumor-associated point mutations decrease receptor expression level and/or receptor tyrosine kinase (RTK) activity. Our study therefore describes a new strategy to mine for novel candidate tumor suppressors and provides compelling evidence that EPHA3 mutations may promote tumorigenesis only when key senescence-inducing pathways have been inactivated. Landes Bioscience 2013-02-15 /pmc/articles/PMC3594263/ /pubmed/23324396 http://dx.doi.org/10.4161/cc.23515 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited. |
spellingShingle | Report Lahtela, Jenni Corson, Laura B. Hemmes, Annabrita Brauer, Matthew J. Koopal, Sonja Lee, James Hunsaker, Thomas L. Jackson, Peter K. Verschuren, Emmy W. A high-content cellular senescence screen identifies candidate tumor suppressors, including EPHA3 |
title | A high-content cellular senescence screen identifies candidate tumor suppressors, including EPHA3 |
title_full | A high-content cellular senescence screen identifies candidate tumor suppressors, including EPHA3 |
title_fullStr | A high-content cellular senescence screen identifies candidate tumor suppressors, including EPHA3 |
title_full_unstemmed | A high-content cellular senescence screen identifies candidate tumor suppressors, including EPHA3 |
title_short | A high-content cellular senescence screen identifies candidate tumor suppressors, including EPHA3 |
title_sort | high-content cellular senescence screen identifies candidate tumor suppressors, including epha3 |
topic | Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3594263/ https://www.ncbi.nlm.nih.gov/pubmed/23324396 http://dx.doi.org/10.4161/cc.23515 |
work_keys_str_mv | AT lahtelajenni ahighcontentcellularsenescencescreenidentifiescandidatetumorsuppressorsincludingepha3 AT corsonlaurab ahighcontentcellularsenescencescreenidentifiescandidatetumorsuppressorsincludingepha3 AT hemmesannabrita ahighcontentcellularsenescencescreenidentifiescandidatetumorsuppressorsincludingepha3 AT brauermatthewj ahighcontentcellularsenescencescreenidentifiescandidatetumorsuppressorsincludingepha3 AT koopalsonja ahighcontentcellularsenescencescreenidentifiescandidatetumorsuppressorsincludingepha3 AT leejames ahighcontentcellularsenescencescreenidentifiescandidatetumorsuppressorsincludingepha3 AT hunsakerthomasl ahighcontentcellularsenescencescreenidentifiescandidatetumorsuppressorsincludingepha3 AT jacksonpeterk ahighcontentcellularsenescencescreenidentifiescandidatetumorsuppressorsincludingepha3 AT verschurenemmyw ahighcontentcellularsenescencescreenidentifiescandidatetumorsuppressorsincludingepha3 AT lahtelajenni highcontentcellularsenescencescreenidentifiescandidatetumorsuppressorsincludingepha3 AT corsonlaurab highcontentcellularsenescencescreenidentifiescandidatetumorsuppressorsincludingepha3 AT hemmesannabrita highcontentcellularsenescencescreenidentifiescandidatetumorsuppressorsincludingepha3 AT brauermatthewj highcontentcellularsenescencescreenidentifiescandidatetumorsuppressorsincludingepha3 AT koopalsonja highcontentcellularsenescencescreenidentifiescandidatetumorsuppressorsincludingepha3 AT leejames highcontentcellularsenescencescreenidentifiescandidatetumorsuppressorsincludingepha3 AT hunsakerthomasl highcontentcellularsenescencescreenidentifiescandidatetumorsuppressorsincludingepha3 AT jacksonpeterk highcontentcellularsenescencescreenidentifiescandidatetumorsuppressorsincludingepha3 AT verschurenemmyw highcontentcellularsenescencescreenidentifiescandidatetumorsuppressorsincludingepha3 |